Clinical Trial

The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis

Study acronym: ExTINGUISH
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Determine the difference in the modified Rankin score at 16 weeks in participants with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis treated with "first-line" immunomodulatory therapies provided as standard-of-care, and either inebilizumab (investigational agent) or placebo.
Protocol Amendment History 13 amendments
This ClinicalTrials.gov record has been amended 13 times since 2020-05-01; most recent amendment 2025-06-30.
Status change: Not Yet Recruiting → Recruiting 2022-04-20
Trial Details
NCT Number NCT04372615
Lead Sponsor University of Utah
Conditions Autoimmune Encephalitis, Encephalitis
Enrollment 116 participants
Start Date 2022-03-30
Primary Completion 2028-09-30 (estimated)
Study Completion 2028-09-30 (estimated)
Updated on ClinicalTrials.gov 2025-07-01